drugset

drugset / Trial / NCT03574545

Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

NCT03574545 ↗

Phase 1 Completed 48 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the safety and pharmacokinetic comparability of two VAY736 drug products in patients with rheumatoid arthritis.

Timeline

Start: 2018-12-19
Primary completion: 2024-07-18
Completion: 2024-07-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ianalumab	Monoclonal antibody	—	—

Indications